Early in the pandemic, one of the locl hospitals was using convalescent plasma to significant benefit for its patients. This has now been replaced by monoclonal antibody infusions. The cited study emphasizes that the level of antibodies in the plasma makes a big difference in the success of the plasma treatment, as common sense would predict.
So, perhaps the most recent recovery patient plasma would have the more active antibodies, than those who recovered from covid a year ago ?